Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iradimed (IRMD) EBT (2016 - 2025)

Historic EBT for Iradimed (IRMD) over the last 13 years, with Q3 2025 value amounting to $7.3 million.

  • Iradimed's EBT rose 1370.15% to $7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.9 million, marking a year-over-year increase of 1398.42%. This contributed to the annual value of $24.3 million for FY2024, which is 1167.16% up from last year.
  • According to the latest figures from Q3 2025, Iradimed's EBT is $7.3 million, which was up 1370.15% from $7.3 million recorded in Q2 2025.
  • Iradimed's EBT's 5-year high stood at $7.3 million during Q2 2025, with a 5-year trough of $1.8 million in Q1 2021.
  • Over the past 5 years, Iradimed's median EBT value was $5.2 million (recorded in 2024), while the average stood at $4.9 million.
  • In the last 5 years, Iradimed's EBT skyrocketed by 36852.38% in 2021 and then rose by 15.27% in 2024.
  • Over the past 5 years, Iradimed's EBT (Quarter) stood at $3.1 million in 2021, then soared by 51.07% to $4.7 million in 2022, then rose by 20.79% to $5.7 million in 2023, then rose by 11.66% to $6.3 million in 2024, then increased by 15.03% to $7.3 million in 2025.
  • Its EBT was $7.3 million in Q3 2025, compared to $7.3 million in Q2 2025 and $5.9 million in Q1 2025.